

## LIBROS

Avioli LV, ed. The osteoporotic syndrome: Detection, prevention and treatment (4.<sup>a</sup> ed). San Diego: Academic Press, 2000.

## NÚMEROS MONOGRÁFICOS

Cannata J, Ortega F, eds. VII Simposio Internacional del Instituto de Investigación Nefrológica: Metabolismo óseo y polimorfismo del gen del receptor de la vitamina D. *Nefrología* 2001; 21: 45-60.

Cowell CT, Wüster C, eds. Analytic methods in clinical osteology. Useful predictors of long-term outcomes or a waste of time and money. *Hormone Res* 2000; 54 (Supl 1): 1-74.

Walker-Bone K, Dennison E, Cooper C. Osteoporosis. *Rheum Dis Clin North Am* 2001; 27: 1-180.

## NUESTROS AUTORES

Montalbán J, Rico H, Cortés J, Pedrera JD. Masa cortical ósea y factores de riesgo para la osteoporosis en mujeres postmenopáusicas de nuestro medio. *Rev Clin Esp* 2001; 201: 16-20.

Espallargues M, Estrada MD, Sampietro L, Granados A. Cribado de la osteoporosis en las personas mayores. *Med Clin (Barc)* 2001; 116 (Supl 1): 77-82.

Armelle M, Martínez V, Medina A, et al. Consejo para la prevención de accidentes y caídas en las personas mayores. *Med Clin (Barc)* 2001; 116 (Supl 1): 106-111.

Fachinetti MM, Russo A. Aging and calcitriol regulation of IP3 production in rat skeletal muscle and intestine. *Hormone Metab Res* 2001; 33: 10-15.

Gussiyev M, Terradas P, Yeste D, et al. Low bone mineral density values in adolescents and young adult Turner syndrome patients increase after long-term transdermal estradiol therapy. *Hormone Res* 2001; 54: 131-135.

**Se ruega a los autores enviar una copia del trabajo para incluir su cita en esta Sección.**

## REVISIONES

Glazier MG, Bowman MA. A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. *Arch Int Med* 2001; 161: 1.161-1.172.

Recker RR, Heaney RP. The role of combination treatment for osteoporosis. *J Clin Endocrinol Metab* 2001; 86: 1.888-1.889.

Balestrieri A, Faustini H, Rochira V, Cerani C. Clinical implications and management of estrogen deficiency in the male. *Clin Endocrinol* 2001; 54: 431-432.

Huddleston J, Whitford KJ. Medical care of elderly patients with hip fractures. *Mayo Clin Prod* 2001; 76: 295-298.

Reginster JY, Christiansen C, Roux C, et al. Intermitent cyclic

tiludronate in the treatment of osteoporosis. *Osteoporosis Int* 2001; 12: 169-177.

Johnell O, Oden A, Caullin F, Kanis JA. Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. *Osteoporosis Int* 2001; 12: 207-214.

Huddleston JM, Witford KJ. Medical care of elderly patients with hip fractures. *Mayo Clin Proc* 2001; 76: 295-298.

Rauch F, Schoenau E. Changes in bone density during childhood and adolescence: an approach based on bone's biological organization. *J Bone Miner Res* 2001; 16: 597-604.

Rosier RN. Expanding the role of the orthopedic surgeon in the treatment of osteoporosis. *Clin Orthop* 2001; 385: 57-67.

Astrom AB, Puchalski CM, Sulmasy DP. Religion, spirituality and health care: social, ethical and practical considerations. *Am J Med* 2001; 110: 283-287.

Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. *Pharmacol Review* 2001; 53: 25-72.

LeBlanc ES, Janowsky J, Chan KBS, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. *JAMA* 2001; 285: 1.489-1.499.

Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. *JAMA* 285: 1.415-1.418.

Fleisch H. Can bisphosphonates be given to patients with fractures? *J Bone Miner Res* 2001; 16: 437-330.

Alexander C. Idiopathic osteoporosis: an evolutionary disadaptation? *Ann Rheum Dis* 2001; 60: 554-558.

Lane NE. An update on glucocorticoid-induced osteoporosis. *Rheum Dis Clin North Am* 2001; 27: 235-253.

Cheung AM. Post-liver transplantation osteoporosis. *J Hepatol* 2001; 34: 337-338. Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. *Rheum Dis Clin North Am* 2001; 27: 255-262.

Peichl P, Griesmacherb A, Marteau R, et al. Osteoporosis in systemic lupus erythematosus: prevention and treatment. *Lupus* 2001; 10: 227-232.

## OTROS ARTÍCULOS DE INTERÉS

Lips P, Doung T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from multiple outcomes of raloxifene evaluation clinical trial. *J Clin Endocrinol Metab* 2001; 86: 1.212-1.221.

Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture. A prospective study. *J Clin Endocrinol Metab* 2001; 86: 32-38.

Hrlich MH, Gerritsen EJA. Formation of non-resorbing osteoclasts from peripheral blood mononuclear cells of patients with malignant juvenile osteopetrosis. *Br J Hematol* 2001; 112: 64.

Nguten TV, Center JR, Sambrook PN, Esiman JA. Risk factors for proximal humerus, forearm, and wrist fractures in elderly men and women. The Dubbo Osteoporosis Epidemiology Study. *Am J Epidemiol* 2001; 153: 587-595.

- Schoon EJ, Müller MCA, Vermeer C et al. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease. *Gut* 2001; 48: 473-477.
- Henini PF, Berlemann U, Kaufma M et al. Augmentation of mechanical properties in osteoporotic vertebral bones a biochemical investigation of vertebroplasty efficacy with different bone cements. *Eur Spine J* 2001; 10: 164-171.
- Lu Y, Genant HK, Shepherd J et al. Classification of osteoporosis based on bone mineral densities. *J Bone Miner Res* 2001; 16: 901-910.
- Baron JA, Farhvard BY, Weiderpass E et al. Cigarette smoking alcohol consumption and risk of hip fracture in women. *Arch In Med* 2001; 161: 983-988.
- Bauer DC, Ettinger B, Nevitt MC et al. Risk for fracture in woman with low serum levels of thyroid-stimulating hormone. *Ann Int Med* 2001; 134: 561-568.
- Skripitz R, Apenberg P. Implant fixation enhancement by intermittent treatment with parathyroid hormone. *J Bone Joint Surg (Br)* 2001; 83-B: 437-440.
- Cauley JA, Black DM, Barrett-Connor E et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). *Am J Med* 2001; 110: 442-450.
- Zborowski JV, Talbott EO, Cauley JA. Polycystic ovary syndrome, androgen excess, and the impact on bone. *Obstet Gynecol Clin North Am* 2001; 28: 135-151.
- Kasper MJ, Peterson MG, Allegrante JP. The need for comprehensive educational osteoporosis prevention programs for young women: results from a second osteoporosis prevention survey. *Arthritis Rheum* 2001; 45: 28-34.
- Gillberg P, Johansson AG, Blum WF et al. Growth hormone secretion and sensitivity in men with idiopathic osteoporosis. *Calcif Tissue Int* 2001; 68: 67-73.
- Stevens HG, Jacobs JW, Van Rijk PP, De Klerk JM. Serum crosslaps in comparison to serum osteocalcin and urinary bone resorption markers. *Clin Biochem* 2001; 34: 131-139.
- Sen D, Keen RW. Methotrexate osteopathy demonstrated by technetium-99m hdp bone scintigraphy. *Clin Nucl Med* 2001; 26: 389-391.
- Yosipovitch G, Hoon TS, Leok GC. Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients. *Arch Dermatol* 2001; 137: 477-481.
- Gooren LJ, Lips P, Gijs L. Osteoporosis and androgen-depleting drugs in sex offenders. *Lancet* 2001; 357: 1208-1209.
- Lewis SJ, Smith PE. Osteoporosis prevention in myasthenia gravis: a reminder. *Acta Neurol Scand* 2001; 103: 320-322.
- Hauge EM, Mosekilde L, Melsen F, Frydenberg M. How many patients are needed? Variation and design considerations in bone histomorphometry. *Bone* 2001; 28: 556-562.
- Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids.